EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antifungal Drugs for the Treatment of Invasive Fungal Infections—A Limited Therapeutic Toolbox Facing Growing Resistances

Victoria Susan, Mylène Lang iD, Marcela Sabou iD, Line Bourel-Bonnet

Pharmaceuticals · 19.08.2025 · 18 (8) · 1220

DOI: 10.3390/ph18081220 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 19.08.2025. Verfasst von Victoria Susan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chemobiology and Pharmacognosy for Health (CPS) Team, Strasbourg Institute for Drug Discovery and Development (ITI IMS), Laboratory of Therapeutic In…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Strasbourg Institute for Advanced Study (USIAS) for a fellowship attributed to LB, within the French national programme 'Investment for the futur…, University of Strasbourg, University of Strasbourg Institute for Advanced Study (USIAS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Invasive fungal infections (IFIs) are one of the most significant public health challenges worldwide. Yet, research and communication thereof were left behind for a long time, until the WHO published a priority pathogens list to guide research, development, and public health action in October 2022. Indeed, due to the rising number of immunocompromised patients at risk and the high level of morbidity, mortality, and economic burden they entail, especially in low- and middle-income countries, IFIs are a serious public health threat. Fungal infections due to dimorphic fungi face additional challenges such as limited knowledge outside of endemic areas and restricted availability of antifungal molecules in areas affected by these infections. The number of related deaths per year is estimated at 2.5 million, but non-governmental organisations make a wider estimation, due to the difficulties in early in vitro diagnostic and troublesome collection and analysis of epidemiological data. Despite this fact, the therapeutic toolbox addressing these infections remains limited, with only four main families of molecules available so far. The antifungal therapeutic supply is composed of very toxic polyenes, the weakly selective and nearly unused 5-fluorocytosine, and azoles, some of which are becoming increasingly inefficient against IFIs. In the 2000–2020s, the fourth arising family consisted of safer semisynthetic echinocandins. Unfortunately, nowadays, more and more fungal isolates encountered in intensive care units exhibit a low susceptibility to echinocandins or are even multiresistant. In this review, we expose the current treatments available to fight against invasive fungal infections. We recall the discovery and physico-chemical aspects of these substances leading to structure/activity and structure/properties relationships. We particularly focus on the to-date resistances and their molecular mechanisms. We finally list some of the most relevant antifungal drug candidates, as they were freshly overviewed by the World Health Organization in April 2025, highlighting the importance of the molecular dimension of this pursuit toward the expansion of the antifungal therapeutic toolbox.

Schlagwörter

Stichwörter der Autor:innen

antifungalsdrug candidatesinvasive fungal infectionsresistancestructure–activity relationships

Autor:innen und Institutionen

  • Chemobiology and Pharmacognosy for Health (CPS) Team, Strasbourg Institute for Drug Discovery and Development (ITI IMS), Laboratory of Therapeutic Innovation (LIT), UMR 7200 CNRS/Unistra, Faculty of Pharmacy, 74, Route…
  • University of Strasbourg Institute for Advanced Studies (USIAS), 67000 Strasbourg, France.
  • Strasbourg Institute of Parasitology and Tropical Pathology, Strasbourg University Hospital, 1-3 Rue Koeberlé, 67000 Strasbourg, France.

ORCID-Profile: Mylène Lang, Marcela Sabou

Förderung

  • University of Strasbourg Institute for Advanced Study (USIAS) for a fellowship attributed to LB, within the French national programme 'Investment for the futur…
  • University of Strasbourg
  • University of Strasbourg Institute for Advanced Study (USIAS)

Zitieren

APA

Susan, V., Lang, M., Sabou, M., & Bourel-Bonnet, L. (2025). Antifungal Drugs for the Treatment of Invasive Fungal Infections—A Limited Therapeutic Toolbox Facing Growing Resistances. Pharmaceuticals, 18(8), 1220. https://doi.org/10.3390/ph18081220

Vancouver

Susan V, Lang M, Sabou M, Bourel-Bonnet L. Antifungal Drugs for the Treatment of Invasive Fungal Infections—A Limited Therapeutic Toolbox Facing Growing Resistances. Pharmaceuticals. 2025;18(8):1220. doi:10.3390/ph18081220

BibTeX
@article{Susan2025,
  author = {Susan, Victoria and Lang, Mylène and Sabou, Marcela and Bourel-Bonnet, Line},
  title = {Antifungal Drugs for the Treatment of Invasive Fungal Infections—A Limited Therapeutic Toolbox Facing Growing Resistances},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {1220},
  doi = {10.3390/ph18081220}
}
Kostenlos starten →